Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.
  • Drug Patent & Exclusivity Expiration Report - Week of Feb 03 2024

    2025-02-03

    This week, there are 4 drugs in the patent and exclusivity list. They are: - BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB - AMERICAN REGENT INC's INJECTAFER, containing active ingredient FERRIC CARBOXYMALTOSE - ABBVIE INC's KYBELLA, containing active ingredient DEOXYCHOLIC ACID - MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC's ZOLINZA, containing active ingredient VORINOSTAT Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Jan 27 2024

    2025-01-27

    This week, there are 10 drugs in the patent and exclusivity list. They are: - Myfembree by Sumitomo Pharma Switzerland, containing active ingredient Estradiol, Norethindrone Acetate, and Relugolix - Orgovyx by Sumitomo Pharma Switzerland, containing active ingredient Relugolix - Nulibry by Sentynl Therapeutics, containing active ingredient Fosdenopterin Hydrobromide - Delstrigo by Merck Sharp and Dohme, containing active ingredient Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate - Pifeltro by Merck Sharp and Dohme, containing active ingredient Doravirine - Geodon by Viatris Specialty, containing active ingredient Ziprasidone Hydrochloride - Reyvow by Eli Lilly, containing active ingredient Lasmiditan Succinate - Cabenuva Kit by ViiV Healthcare, containing active ingredient Cabotegravir and Rilpivirine - Vocabria by ViiV Healthcare, containing active ingredient Cabotegravir Sodium - Imbruvica by Pharmacyclics, containing active ingredient Ibrutinib Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Jan 20 2024

    2025-01-20

    This week, there are 7 drugs in the patent and exclusivity list. They are: - CUMBERLAND PHARMACEUTICALS INC's SANCUSO, containing active ingredient GRANISETRON - AZURITY PHARMACEUTICALS INC's HORIZANT, containing active ingredient GABAPENTIN ENACARBIL - GILEAD SCIENCES INC's VEKLURY, containing active ingredient REMDESIVIR - ASTRAZENECA AB's BYDUREON BCISE, containing active ingredient EXENATIDE SYNTHETIC - EPIZYME INC's TAZVERIK, containing active ingredient TAZEMETOSTAT HYDROBROMIDE - EVOFEM INC's SOLOSEC, containing active ingredient SECNIDAZOLE - ADVANCED ACCELERATOR APPLICATIONS USA INC's LUTATHERA, containing active ingredient LUTETIUM LU 177 DOTATATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Jan 13 2024

    2025-01-13

    This week, there are 6 drugs in the patent and exclusivity list. They are: - BAUSCH AND LOMB INC's BEPREVE, containing active ingredient BEPOTASTINE BESILATE - ITALFARMACO SPA's DUVYZAT, containing active ingredient GIVINOSTAT HYDROCHLORIDE - NOVARTIS PHARMACEUTICALS CORP's ENTRESTO & ENTRESTO SPRINKLE, containing active ingredient SACUBITRIL; VALSARTAN - GLENMARK SPECIALTY SA's RYALTRIS, containing active ingredient MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - ABBVIE INC's RINVOQ, containing active ingredient UPADACITINIB Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Jan 06 2024

    2025-01-06

    This week, there are 8 drugs in the patent and exclusivity list. They are: - AZURITY PHARMACEUTICALS INC's EDARBI, containing active ingredient AZILSARTAN KAMEDOXOMIL - ABBVIE INC's TRILIPIX, containing active ingredient CHOLINE FENOFIBRATE - AZURITY PHARMACEUTICALS INC's EDARBYCLOR, containing active ingredient AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - TEVA NEUROSCIENCE INC's UZEDY, containing active ingredient RISPERIDONE - TEVA PHARMACEUTICAL INDUSTRIES LTD's AIRDUO RESPICLICK, containing active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - BLUEPRINT MEDICINES CORP's AYVAKIT, containing active ingredient AVAPRITINIB - BOEHRINGER INGELHEIM's GILOTRIF, containing active ingredient AFATINIB DIMALEATE - CEPHALON INC's TRISENOX, containing active ingredient ARSENIC TRIOXIDE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Dec 30 2024

    2024-12-30

    This week, there is 1 drug in the patent and exclusivity list. It is: - BAUSCH AND LOMB INC's VYZULTA, containing active ingredient LATANOPROSTENE BUNOD Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Dec 23 2024

    2024-12-23

    This week, there are 4 drugs in the patent and exclusivity list. They are: - STEMLINE THERAPEUTICS INC's ORSERDU, containing active ingredient ELACESTRANT DIHYDROCHLORIDE - ABBVIE INC's UBRELVY, containing active ingredient UBROGEPANT - TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC's AUSTEDO, containing active ingredient DEUTETRABENAZINE - OTSUKA PHARMACEUTICAL CO LTD's REXULTI, containing active ingredient BREXPIPRAZOLE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Dec 16 2024

    2024-12-16

    This week, there are 16 drugs in the patent and exclusivity list. They are: - UNITED THERAPEUTICS CORP's REMODULIN, containing active ingredient TREPROSTINIL - VALINOR PHARMA LLC's MOVANTIK, containing active ingredient NALOXEGOL OXALATE - OTSUKA PHARMACEUTICAL CO LTD's ABILIFY, containing active ingredient ARIPIPRAZOLE - INTRA-CELLULAR THERAPIES INC's CAPLYTA, containing active ingredient LUMATEPERONE TOSYLATE - PFIZER INC's TOVIAZ, containing active ingredient FESOTERODINE FUMARATE - CUBIST PHARMACEUTICALS LLC's ZERBAXA, containing active ingredient CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - EISAI INC's LENVIMA, containing active ingredient LENVATINIB MESYLATE - PF PRISM CV's BOSULIF, containing active ingredient BOSUTINIB MONOHYDRATE - AMGEN INC's OTEZLA, containing active ingredient APREMILAST Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Dec 09 2024

    2024-12-09

    This week, there are 9 drugs in the patent and exclusivity list. They are: - SANDOZ INC's HYCAMTIN, containing active ingredient TOPOTECAN HYDROCHLORIDE - MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC's ZEPATIER, containing active ingredient ELBASVIR; GRAZOPREVIR - NOVARTIS PHARMACEUTICALS CORP's KISQALI FEMARA CO-PACK (COPACKAGED), containing active ingredient LETROZOLE; RIBOCICLIB SUCCINATE - NOVARTIS PHARMACEUTICALS CORP's KISQALI, containing active ingredient RIBOCICLIB SUCCINATE - SAREPTA THERAPEUTICS INC's VYONDYS 53, containing active ingredient GOLODIRSEN - ABBVIE INC's RINVOQ, containing active ingredient UPADACITINIB - PFIZER INC's XELJANZ XR, containing active ingredient TOFACITINIB CITRATE - PF PRISM CV's XELJANZ, containing active ingredient TOFACITINIB CITRATE - CALLIDITAS THERAPEUTICS AB's TARPEYO, containing active ingredient BUDESONIDE Read More
  • Total 2 pages  Go to Page
  • Go